Atlas Trials

A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)

Clinical trial NCT05268952 · UNKNOWN

Trial details

NCT number
NCT05268952
Sponsor
University Hospital, Antwerp
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Neuroendocrine Tumors
Start date
2019-05-27
Primary completion
2025-05-27
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.